Active substance
Rifabutin
- US FDA 5
- Health Canada 1
- US price lines 1
- NHS prices 1
- WHO EML 1
- Safety 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MYCOBUTIN | 150MG | capsule · oral | PFIZER | Prescription | 23 Dec 1992 |
| RIFABUTIN | 150MG | capsule · oral | NOVITIUM PHARMA | Prescription | 17 Dec 2021 |
| RIFABUTIN | 150MG | capsule · oral | PHARMAZONE | Prescription | 19 Mar 2026 |
| RIFABUTIN | 150MG | capsule · oral | ZYDUS LIFESCIENCES | Prescription | 21 Aug 2026 |
| RIFABUTIN | 150MG | capsule · oral | LUPIN | Discontinued | 24 Feb 2014 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MYCOBUTIN | 02063786 | 150 MG | CAPSULE · ORAL | PFIZER CANADA ULC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | RIFABUTIN 150 MG CAPSULE | $8.13629 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Rifabutin 150mg capsules | £90.38 | 30 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.5. Antituberculosis medicines · core
Tuberculosis
Oral > Solid: 150 mg
Safety signals and safety-related labeling changes
- US FDA 20 Nov 2024 MYCOBUTIN — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions - US FDA 1 May 2024 TALICIA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.